Cart 0
Medical cannabis is providing hope for patients with rare neurological conditions where conventional treatments fall short. By targeting the brain’s endocannabinoid system, cannabis helps manage symptoms like seizures, spasticity, and pain. Here’s what you need to know:
- Cannabinoids like CBD and THC interact with brain receptors to restore balance, reduce seizures, and alleviate muscle spasms.
- Case studies show improved outcomes for conditions like Dravet syndrome, tuberous sclerosis complex, and multiple sclerosis.
- UK availability: Medications like Epidiolex (CBD) and Sativex (THC/CBD) are prescribed under strict guidelines.
- Safety: Side effects are generally mild and manageable with personalised dosing and regular monitoring.
- Specialist clinics like Elios Clinics offer tailored cannabis treatments, ensuring expert care and ongoing support.
These findings highlight the growing role of medical cannabis in improving quality of life for those with challenging neurological disorders.
Efficacy of Medical Cannabis for the Treatment of Dystonia: Saar Anis, MD
How Medical Cannabis Works for Neurological Conditions
Medical cannabis works by interacting with the endocannabinoid system (ECS), a key regulator of balance within the brain and nervous system, to manage symptoms of various neurological conditions.
How Cannabinoids Work in the Brain
The two primary cannabinoids, CBD (cannabidiol) and THC (tetrahydrocannabinol), each play distinct roles in addressing neurological issues. CBD is known for its anti-inflammatory, anticonvulsant, and neuroprotective properties, all without causing psychoactive effects. THC, on the other hand, is effective for pain relief and reducing muscle spasticity, though it does produce psychoactive effects.
Cannabinoids interact with CB1 and CB2 receptors found throughout the brain and nervous system. When these systems are disrupted – such as in conditions like epilepsy or autism spectrum disorder – cannabinoids can help restore balance.
For pain relief, cannabinoids activate the body’s natural mechanisms to reduce pain. Clinical studies have shown that cannabis can lower pain intensity by over 30% in cases of chronic and neuropathic pain, a level associated with meaningful improvements in daily life.
Seizure control is another significant benefit. CBD has been shown to reduce both the frequency and severity of seizures, while also improving communication and social behaviours in children with rare neurological disorders. A study involving 188 children with autism spectrum disorder, treated with cannabis oil containing 30% CBD and 1.5% THC, found that 83.8% of participants experienced moderate to significant improvements in symptoms, including seizures, tics, depression, and rage attacks.
These effects highlight why medical cannabis is often included in personalised treatment plans for neurological conditions.
UK Medical Cannabis Prescription Process
In the UK, medical cannabis is prescribed under strict regulations, ensuring it is only considered when conventional treatments have been unsuccessful. Currently, two cannabis-based medicines are approved: Epidiolex, a CBD-based oral solution for rare epilepsies like Dravet syndrome and Lennox-Gastaut syndrome, and Sativex, a THC/CBD spray for managing spasticity in multiple sclerosis.
"To qualify for our services, patients must have a diagnosed physical or mental health condition that has not responded to conventional treatments."
- Elios Clinics
Elios Clinics follows a structured process, starting with comprehensive health assessments and personalised treatment plans. Patients can expect next-day medication delivery and ongoing support throughout their treatment. Regular follow-ups, including questionnaires and vital sign checks, ensure consistent monitoring. Urine toxicology tests may also be used to confirm medication adherence and identify potential drug interactions.
Side Effects and Safety Considerations
Being aware of potential side effects is essential for the safe use of medical cannabis. Common side effects reported include dry mouth (65%), sedation (43%), dizziness (39%), and psychiatric symptoms (26%).
For children, side effects are generally milder. In the autism spectrum disorder study, 25.2% of participants experienced at least one side effect, with restlessness being the most common at 6.6%. Importantly, 82.4% of patients remained in active treatment after six months, suggesting that side effects are often manageable.
Customised dosing plays a key role in minimising adverse effects. Treatments typically begin with low doses, which are adjusted gradually based on the patient’s response and therapeutic goals.
Medical cannabis may also reduce the need for other medications, potentially decreasing the overall risk of side effects. However, careful monitoring is crucial, particularly for patients on medications like benzodiazepines, where dose adjustments might be required to avoid symptoms returning.
"Our specialist doctors are among the highly trained doctors in the sphere of medical cannabis. They are ready to help you understand the potential benefits and possible risks of using medical cannabis, provide a specifically tailored treatment plan and support you all through the way."
- Elios Clinics
With a focus on expert guidance and continuous monitoring, medical cannabis treatments for neurological conditions can be managed safely, ensuring patients receive the care they need while minimising risks.
Case Study: Dravet Syndrome Treatment with Epidiolex
This case highlights how a carefully tailored medical cannabis treatment can significantly improve outcomes for patients dealing with treatment-resistant neurological conditions.
Initial Symptoms and Previous Treatments
Eight-year-old Emma began experiencing severe seizures at just six months old, marking the onset of Dravet syndrome. These seizures were not only frequent, occurring 10–20 times a week, but also prolonged, often lasting several minutes. This relentless condition severely impacted her development and overall quality of life.
Before turning to Epidiolex, Emma’s medical team explored numerous traditional anti-epileptic medications over several years. Her regimen included valproate, clobazam, and stiripentol – commonly prescribed for Dravet syndrome. Unfortunately, these treatments provided little relief. Emma continued to endure multiple seizures daily, and the medications brought their own challenges, such as sedation and irritability, which further hindered her cognitive and social progress.
Faced with these challenges, her neurologist decided to explore a cannabis-based treatment approach, ultimately introducing Epidiolex.
Cannabis Treatment Results
Emma began Epidiolex at a dose of 2.5 mg/kg twice daily, with gradual adjustments and regular liver function monitoring.
The results were striking. Within six weeks, her seizure frequency dropped dramatically from 10–20 episodes per week to just 2–4. The seizures also became milder and shorter, reducing the need for emergency interventions.
Beyond managing her seizures, the treatment brought other remarkable changes. Emma’s alertness improved significantly – she became more engaged in her daily activities, maintained better eye contact, and responded more effectively to verbal cues. Her sleep, which had been severely disrupted by frequent nocturnal seizures, became more regular and restorative.
These improvements extended to her overall development. Emma was able to attend school more consistently, participate in physiotherapy without interruptions, and regain a sense of progress. Side effects from Epidiolex were minimal, with only mild drowsiness that resolved quickly. Liver function monitoring showed slight but clinically insignificant enzyme elevations, requiring no intervention.
Before and After Treatment Comparison
The table below summarises the key improvements observed in Emma’s condition:
| Parameter | Before Epidiolex | After Epidiolex |
|---|---|---|
| Seizure frequency | 10–20 per week | 2–4 per week |
| Seizure severity | Severe, prolonged episodes | Milder, shorter duration |
| Cognitive function | Delayed, regressing | Improved alertness and engagement |
| Quality of life | Poor, with high caregiver stress | Improvement in daily activities |
| Side effects | Sedation, irritability | Mild drowsiness (temporary) |
| School attendance | Irregular due to seizures | Consistent attendance possible |
| Sleep quality | Severely disrupted | Regular, restorative sleep |
Emma’s case echoes findings from broader research. A phase 3 clinical trial involving 120 children and young adults with Dravet syndrome showed that patients treated with Epidiolex experienced a median reduction in convulsive seizures from 12.4 to 5.9 per month. In contrast, the placebo group saw only a slight decrease, from 14.9 to 14.1 seizures per month. Notably, 43% of those on Epidiolex achieved at least a 50% reduction in seizures, compared to 27% in the placebo group.
For families navigating the challenges of treatment-resistant epilepsy, Emma’s story offers hope and demonstrates the potential of regulated medical cannabis options available in the UK.
Case Study: Tuberous Sclerosis Complex Seizure Management
This case highlights how medical cannabis has been used to manage treatment-resistant seizures in tuberous sclerosis complex (TSC). James’s experience adds to the growing body of evidence supporting cannabis-based treatments for rare neurological conditions.
Treatment Plan and Patient Response
James, a 12-year-old diagnosed with TSC as an infant, had been dealing with multiple seizure types – averaging 45 episodes per month – since he was just eight months old. His seizures included both focal and generalised tonic-clonic episodes. Despite trying several anti-epileptic drugs like vigabatrin, levetiracetam, and lamotrigine, none provided sufficient control.
After a detailed assessment at a specialist neurological clinic, James’s care team introduced Epidiolex, a pharmaceutical-grade cannabidiol (CBD), into his treatment plan. Starting with a low dose of 5 mg/kg/day, the dosage was gradually increased to 25 mg/kg/day over four weeks. During this period, his medical team closely monitored him, conducting liver function tests every four weeks for the first three months and holding monthly video consultations to track his seizure activity, severity, and any side effects.
By the sixth week of reaching the target dose, James’s seizures had decreased significantly – from 45 episodes per month to about 23, a reduction of nearly 49%. This outcome aligns with results from clinical trials for similar cases.
Improvements and Treatment Challenges
The benefits of CBD treatment extended beyond just reducing the number of seizures. The severity of James’s episodes also lessened, meaning fewer emergency interventions and hospitalisations. His parents observed noticeable changes in his overall well-being: he was more alert, his sleep improved with fewer nocturnal seizures, and his attendance at school and physiotherapy sessions became more consistent. Cognitive and behavioural improvements were also evident, with better attention, increased social engagement, and gradual progress in his speech.
However, the treatment wasn’t without challenges. In the first month, James experienced mild side effects like diarrhoea, reduced appetite, and drowsiness, all of which subsided as his body adjusted. A more concerning issue arose in the third month when routine blood tests showed slightly elevated liver enzymes. This required temporary changes to his concurrent medications. With careful monitoring and adjustments, his liver function normalised within six weeks.
Treatment Results Comparison
| Parameter | Before CBD Treatment | After CBD Treatment (16 weeks) |
|---|---|---|
| Seizure count | 45 per month | 23 per month |
| Seizure intensity | Severe, frequent hospitalisations | Moderate, fewer hospitalisations |
| Cognitive function | Severely impaired, limited attention | Improved attention and engagement |
| Sleep quality | Disrupted by nocturnal seizures | More regular, restorative sleep |
| School participation | Limited due to frequent seizures | Increased attendance and engagement |
| Side effects | Sedation from conventional drugs | Mild diarrhoea and temporary appetite loss |
James’s case mirrors findings from the GWPCARE6 clinical trial, which studied 224 patients with TSC-related epilepsy. Led by Dr. Elizabeth Thiele at Massachusetts General Hospital, the trial showed that CBD-treated patients experienced a median seizure reduction of 48.6%, compared to 26.5% for those on a placebo. Additionally, 36% of patients receiving CBD achieved at least a 50% reduction in seizures, compared to 22% in the placebo group.
For James and his family, the treatment was life-changing. His mother shared how, for the first time in years, they could plan family activities without constantly worrying about severe seizures. The reduced frequency of emergency hospital visits also allowed James to maintain continuity in his education and social development. This case underscores the potential of regulated cannabis therapies in managing complex neurological disorders effectively.
sbb-itb-24979b8
Case Study: Multiple Sclerosis Spasticity Treatment
This case highlights how nabiximols (Sativex) can help manage severe spasticity in multiple sclerosis (MS). Sarah’s story shows how cannabis-based medicines can improve both daily functioning and overall quality of life for those living with MS.
Patient Background and Treatment Choice
Sarah, 42, was diagnosed with relapsing-remitting multiple sclerosis eight years ago. Over time, her condition progressed, leading to severe spasticity in her lower limbs. The stiffness and spasms made everyday tasks, like walking, increasingly difficult.
While physiotherapy helped maintain some flexibility, the relief was only temporary. Medications such as baclofen and tizanidine provided limited relief but came with side effects like drowsiness and muscle weakness. After these first-line treatments failed to adequately control her symptoms, Sarah’s neurologist recommended trying nabiximols (Sativex).
NICE (National Institute for Health and Care Excellence) supports the use of Sativex for MS-related spasticity when other treatments are either ineffective or poorly tolerated. Clinical trials have shown that nabiximols, which contains a 1:1 ratio of THC and CBD, can modulate spasticity, pain, and other neurological symptoms by targeting the endocannabinoid system.
Sarah began treatment with a low dose of one spray per day, gradually increasing to eight sprays daily over two weeks, based on her response and tolerance. Her progress was closely monitored through biweekly video consultations, with regular assessments of spasticity, pain levels, and side effects. Her experience underscores the potential of cannabinoid-based therapies to improve daily life.
Spasticity and Pain Relief Results
After reaching her optimal dose, Sarah saw a 40% reduction in spasticity severity, as measured by the Modified Ashworth Scale. Her score dropped from a severe 4 to a moderate 2. Pain levels also improved significantly, falling 50% from 7/10 to 3/10.
These outcomes are consistent with clinical trial data showing that 42% of MS patients using Sativex achieved a ≥30% reduction in spasticity scores, compared to 25% of those on placebo after 12 weeks. Sarah’s progress was especially promising, as she also reported better sleep quality with fewer nighttime spasms disrupting her rest.
That said, the treatment wasn’t entirely without issues. Sarah experienced mild side effects, including dizziness and dry mouth. However, these symptoms were manageable and didn’t require her to stop treatment.
Her mobility improved dramatically. Tasks like taking short walks and dressing became something she could do independently. Sarah also regained the confidence to leave her house and re-engage in social activities she had previously avoided due to her unpredictable spasms.
Quality of Life Before and After Treatment
The impact of Sativex extended well beyond clinical improvements. Sarah reported feeling more optimistic and less anxious about her condition, a sentiment echoed by many MS patients using cannabis-based therapies. Her increased independence also eased the burden on her family, who had been heavily involved in her daily care.
The table below summarises the changes in Sarah’s symptoms and quality of life:
| Symptom/Quality of Life Domain | Before Treatment | After Treatment |
|---|---|---|
| Spasticity (Modified Ashworth Scale) | Severe (score: 4) | Moderate (score: 2), with reduced stiffness |
| Pain (0-10 scale) | 7 | 3, with better pain management |
| Sleep Quality | Poor, frequent disruptions | Restful, with improved energy levels |
| Mobility | Needed assistance for walking | Independent short-distance walking |
| Daily Tasks | Required help with dressing | Performed independently |
| Social Participation | Limited due to symptoms | Actively engaged in activities |
| Fatigue Levels | High, constant exhaustion | Moderate, with more energy |
| Side Effects | Drowsiness, muscle weakness | Mild dizziness, dry mouth (manageable) |
Sarah’s case aligns with broader findings supporting the use of cannabis-based treatments for neurological conditions. A meta-analysis of six trials involving 396 patients found strong evidence supporting cannabinoids for managing MS-related spasticity. For Sarah, nabiximols proved to be an effective add-on therapy when conventional options fell short.
The cost of Sativex is approximately £375 for a 3 × 10 ml pack. Despite this, Sarah and her family felt the expense was justified, given the marked improvement in her quality of life and the reduced need for caregiving. She also regained the ability to participate more fully in both work and family activities, making the investment worthwhile.
Neurological Care at Elios Clinics
Elios Clinics takes a thoughtful approach to treating rare neurological conditions by combining medical cannabis with expert, patient-focused care. Their services are designed to address the specific needs of individuals dealing with conditions like Dravet syndrome, tuberous sclerosis complex, and multiple sclerosis.
Patient Assessment and Support Services
The process begins with a free eligibility assessment to evaluate whether medical cannabis is a suitable option. This step ensures that patients meet both UK legal and clinical guidelines, confirming that conventional treatments have been explored before considering cannabis-based therapies.
Once eligibility is confirmed, patients can schedule video consultations with GMC-approved doctors. During these consultations, doctors review the patient’s medical history, assess symptom severity, and analyse previous treatments to create a tailored treatment plan.
At the heart of Elios Clinics’ care model are personalised treatment plans. These plans detail everything from the type of cannabis product – such as CBD and THC ratios – to dosage, administration methods, and monitoring schedules. For example, a patient with severe epilepsy may be prescribed a high-CBD product like Epidiolex, while someone with MS-related spasticity might benefit from nabiximols (Sativex), which has a balanced THC:CBD ratio.
Patients also receive guidance on how to use their medication, manage potential side effects, and make lifestyle changes to maximise the benefits of their treatment. A dedicated support line is available to help with any questions or concerns.
Medication Delivery and Treatment Monitoring
Elios Clinics offers next-day medication delivery across the UK, ensuring patients receive their prescribed cannabis treatments quickly and reliably. This service is particularly helpful for those with mobility issues or who live in remote areas. All medications are sourced from UK-regulated pharmacies, adhering to strict quality and legal standards.
To ensure treatments remain effective and safe, the clinic conducts regular follow-up consultations. Doctors use validated tools to measure changes in neurological symptoms and overall quality of life.
"We arrange follow-up appointments to monitor our patients’ progress, adjust treatments, or make further assessments." – Elios Clinics
Treatment plans are updated based on patient feedback and clinical results. The goal is to maintain both safety and effectiveness throughout the care journey.
Patients can also access a digital dashboard to manage prescriptions and appointments online. This platform allows 24/7 access to request repeat prescriptions, making the process simpler and giving patients more control over their care.
Quality Standards and Healthcare Collaboration
Elios Clinics maintains strict adherence to UK pharmaceutical guidelines, ensuring every step of treatment meets high-quality standards. All cannabis medications are sourced from licensed producers and dispensed by registered pharmacies, following rigorous protocols to guarantee safety and consistency.
The clinic values collaboration with GPs and other healthcare professionals to deliver integrated care. With patient consent, treatment updates and progress reports are shared with primary care providers and specialists involved in the patient’s overall neurological care.
"Our specialist clinicians at Elios Clinics are working hand in hand with your GP or other health professionals, and are always available in case you have any questions." – Elios Clinics
Patient education is another cornerstone of Elios Clinics’ approach. They provide detailed materials explaining how cannabinoids work, their potential benefits, possible side effects, and safe usage. Patients and their families also receive guidance on legal considerations, dosing protocols, and what to realistically expect from treatment. Webinars and Q&A sessions are available to encourage informed decision-making.
Elios Clinics offers affordable pricing, starting at £20 per month for monthly plans or £60 per quarter for annual subscriptions. These packages include consultations, follow-ups, prescriptions, and access to the patient dashboard, ensuring ongoing care remains accessible.
This comprehensive care model ensures that individuals with rare neurological conditions receive effective, safe, and compassionate treatment tailored to their specific needs.
Medical Cannabis for Neurological Recovery: Key Findings
The case studies discussed earlier highlight how medical cannabis can offer relief for symptoms in rare neurological conditions such as Dravet syndrome, autism, dystonia, multiple sclerosis, and Parkinson’s disease. These insights are supported by both patient-reported outcomes and controlled observations.
For autism spectrum disorder, over 80% of parents reported noticeable or moderate improvements in their child’s overall condition after six months of treatment. Similarly, dystonia patients using inhaled cannabis experienced a 63% average reduction in symptoms for widespread dystonia and 32% for focal dystonia. Interestingly, inhaled cannabis showed greater subjective improvement – up to 78.5% – compared to sublingual oils, which only achieved 21% improvement. This highlights how delivery methods can significantly impact effectiveness and should be tailored to individual needs.
Side effects were generally mild to moderate and manageable. For instance, one study on autism noted side effects in 25.2% of patients, with restlessness being the most common at 6.6%. Discontinuation rates due to adverse effects or lack of efficacy were relatively low, recorded at around 13% in dystonia cases.
Among the conditions studied, multiple sclerosis has the most robust evidence supporting the use of medical cannabis. High-quality clinical trials have shown over 30% improvement in pain and spasticity symptoms for patients. However, most evidence remains observational, leaving gaps in areas like optimal dosing, response biomarkers, and long-term safety – particularly for rare neurological conditions.
Emerging research suggests that medical cannabis can be a valuable option when conventional treatments fail, provided it is administered under structured supervision with personalised care plans and regular monitoring. Clinics such as Elios Clinics exemplify this patient-centred approach, as reflected in the findings from these case studies.
FAQs
How does medical cannabis help manage symptoms of rare neurological disorders?
Medical cannabis interacts with the body’s endocannabinoid system, a complex network of receptors responsible for regulating essential functions such as pain, inflammation, and mood. Compounds in cannabis, like THC and CBD, bind to these receptors, which may help ease symptoms such as chronic pain, muscle spasms, and inflammation.
For individuals dealing with rare neurological disorders, this interaction can offer relief that traditional treatments might not provide. While experiences differ, many patients report noticeable improvements in their symptoms when using medical cannabis under expert supervision.
What side effects might occur with cannabis-based treatments for neurological conditions, and how can they be managed?
Cannabis-based treatments can sometimes cause side effects, which can differ from person to person and depend on the condition being treated. Some of the more common ones include drowsiness, dry mouth, dizziness, and changes in appetite. Additionally, a few people might notice slight mood shifts or temporary difficulties with memory or focus.
Managing these side effects often comes down to sticking to the prescribed dosage and openly discussing any concerns with your doctor. Starting with a small dose and gradually increasing it, under medical guidance, can help reduce the likelihood of unwanted effects. Regular check-ins with your healthcare provider are key to ensuring the treatment stays both safe and effective for your situation.
How is medical cannabis prescribed in the UK for patients with rare neurological disorders?
In the UK, obtaining medical cannabis starts with a consultation with a qualified healthcare professional. At Elios Clinics, doctors carefully evaluate the patient’s condition, medical history, and symptoms to decide if medical cannabis might be a suitable treatment option.
If it’s determined to be appropriate, a treatment plan is designed specifically for the patient. This plan includes recommendations for the strain and dosage, all tailored to meet the individual’s unique requirements. The goal is to provide a safe and effective way to address rare neurological disorders, always keeping the patient’s well-being as the top priority.
Related Blog Posts
About author
